{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:03Z","timestamp":1792592343566,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02789-w","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:58:18Z","timestamp":1770447498000},"page":"1173-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Influence of genetics on clinical trajectories in children with MASLD: role of the PNPLA3 I148M polymorphism"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-3757","authenticated-orcid":false,"given":"Anna","family":"Di Sessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina Rosaria","family":"Umano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelsomina","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Marzuillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Miraglia del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"2789_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41575-025-01045-z","volume":"22","author":"CD Byrne","year":"2025","unstructured":"Byrne CD, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E (2025) Metabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment. Nat Rev Gastroenterol Hepatol 22:314\u2013328","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2789_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2025.10.001","author":"M Esposito","year":"2025","unstructured":"Esposito M, Rimauro I, Frattolillo V, Forcina G, Marzuillo P, Miraglia Del Giudice E, Di Sessa A (2025) MASLD in childhood as a multisystem health challenge beyond the liver. Trends Endocrinol Metab. 2025 Oct 28:S1043-2760(25)00222-X. https:\/\/doi.org\/10.1016\/j.tem.2025.10.001","journal-title":"Trends Endocrinol Metab"},{"key":"2789_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16133","volume":"45","author":"S Petta","year":"2025","unstructured":"Petta S, Armandi A, Bugianesi E (2025) Impact of PNPLA3 I148M on clinical outcomes in patients with MASLD. Liver Int 45:e16133","journal-title":"Liver Int"},{"key":"2789_CR4","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E, Lassailly G, De Vincentis A, Vespasiani-Gentilucci U et al (2024) Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 30:3624\u20133633","journal-title":"Nat Med"},{"key":"2789_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.035","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F et al (2025) High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J Hepatol. 83(4):849\u2013859. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.035","journal-title":"J Hepatol"},{"key":"2789_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/apt.70256","volume":"62","author":"M Kubina","year":"2025","unstructured":"Kubina M, Prasitsumrit V, Tan J, Quek JWE, Peddu D, Mishra A et al (2025) Meta-analysis: effects of steatotic liver disease-associated genetic risk alleles on longitudinal outcomes. Aliment Pharmacol Ther 62:244\u2013276","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2789_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16010","volume":"45","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Targher G (2025) PNPLA3 variation and kidney disease. Liver Int 45(3):e16010","journal-title":"Liver Int"},{"issue":"6","key":"2789_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.diabet.2020.02.001","volume":"46","author":"DS Hu","year":"2020","unstructured":"Hu DS, Zhu SH, Liu WY, Pan XY, Zhu PW, Li YY, Zheng KI, Ma HL, You J, Targher G, Byrne CD, Chen YP, Zheng MH (2020) PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab 46(6):496\u2013503","journal-title":"Diabetes Metab"},{"issue":"7","key":"2789_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2337\/db24-0923","volume":"74","author":"Y Ma","year":"2025","unstructured":"Ma Y, Zuo S, Lo T, Phan D, Finley T, Mackay A, Trigo E, Hartiala JA, Allayee H, Xiang AH, Buchanan TA, Watanabe RM (2025) Genetic variations in GCKR and PNPLA3 regulate metabolic balance across the liver. Diabetes 74(7):1300\u20131309","journal-title":"Diabetes"},{"issue":"8","key":"2789_CR10","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/biomedicines13081977","volume":"13","author":"D Clayton-Chubb","year":"2025","unstructured":"Clayton-Chubb D, Majeed A, Kemp WW, Yu C, Lange PW, Fitzpatrick JA, Woods RL, Tonkin AM, Chan AT, Nelson MR, Ryan J, Hodge AD, Lubel JS, Schneider HG, McNeil JJ, Roberts SK (2025) Genetic variants, metabolic dysfunction-associated fatty liver disease, and major health outcomes in older adults. Biomedicines 13(8):1977","journal-title":"Biomedicines"},{"key":"2789_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41366-024-01674-5","volume":"49","author":"A Di Sessa","year":"2025","unstructured":"Di Sessa A, Zarrilli S, Forcina G, Frattolillo V, Camponesco O, Migliaccio C et al (2025) Role of metabolic dysfunction-associated steatotic liver disease and of its genetics on kidney function in childhood obesity. Int J Obes (Lond) 49:605\u2013611","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"2789_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.2471\/BLT.07.043497","volume":"85","author":"M de Onis","year":"2007","unstructured":"de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J (2007) Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 85(9):660\u20137","journal-title":"Bull World Health Organ"},{"key":"2789_CR13","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EJE-20-0051","volume":"183","author":"M Salerno","year":"2020","unstructured":"Salerno M, Improda N, Capalbo D (2020) MANAGEMENT OF ENDOCRINE DISEASE subclinical hypothyroidism in children. Eur J Endocrinol 183:R13\u2013R28","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2789_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"Haller MJ, Bell KJ, Besser REJ, Casteels K, Couper JJ, Craig ME, Elding Larsson H, Jacobsen L, Lange K, Oron T, Sims EK, Speake C, Tosur M, Ulivi F, Ziegler AG, Wherrett DK, Marcovecchio ML (2024) ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve Beta-Cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr 97(6):529\u2013545","journal-title":"Horm Res Paediatr"},{"key":"2789_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-016-3367-8","volume":"31","author":"L Correia-Costa","year":"2016","unstructured":"Correia-Costa L, Schaefer F, Afonso AC et al (2016) Normalization of glomerular filtration rate in obese children. Pediatr Nephrol 31:1321\u20131328","journal-title":"Pediatr Nephrol"},{"key":"2789_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1741-7015-7-21","volume":"7","author":"V Nobili","year":"2009","unstructured":"Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G (2009) The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 7:21","journal-title":"BMC Med"},{"key":"2789_CR17","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79:1542\u20131556","journal-title":"J Hepatol"},{"key":"2789_CR18","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.jhep.2023.10.021","volume":"80","author":"A Di Sessa","year":"2024","unstructured":"Di Sessa A, Guarino S, Umano GR et al (2024) MASLD vs. NAFLD: a better definition for children with obesity at higher risk of kidney damage. J Hepatol 80:e87\u2013e89","journal-title":"J Hepatol"},{"issue":"6","key":"2789_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000527834","volume":"8","author":"H Liu","year":"2022","unstructured":"Liu H, Zhang C, Xiong J (2022) Pathological connections between nonalcoholic fatty liver disease and chronic kidney disease. Kidney Dis (Basel) 8(6):458\u2013465","journal-title":"Kidney Dis (Basel)"},{"issue":"4","key":"2789_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.15403\/jgld-506","volume":"28","author":"V Karamfilova","year":"2019","unstructured":"Karamfilova V, Gateva A, Assyov Y, Alexiev A, Savov A, Yaneva N, Ivanova I, Ivanova-Boyanova R, Ivanova R, Vlahova Z, Mateva L, Kamenov Z (2019) PNPLA3 I148M polymorphism in patients with nonalcoholic fatty liver disease, obesity and prediabetes. J Gastrointestin Liver Dis 28(4):433\u2013438","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"2789_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/hep.30625","volume":"70","author":"G Targher","year":"2019","unstructured":"Targher G, Mantovani A, Alisi A, Mosca A, Panera N, Byrne CD, Nobili V (2019) Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD. Hepatology 70(1):142\u2013153","journal-title":"Hepatology"},{"issue":"6","key":"2789_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1053\/j.jrn.2022.01.007","volume":"32","author":"A Di Sessa","year":"2022","unstructured":"Di Sessa A, Russo MC, Arienzo MR, Umano GR, Cozzolino D, Cirillo G, Guarino S, Miraglia Del Giudice E, Marzuillo P (2022) PNPLA3 I148M polymorphism influences renal function in children with obesity and prediabetes. J Ren Nutr 32(6):670\u2013676","journal-title":"J Ren Nutr"},{"issue":"47","key":"2789_CR23","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.3748\/wjg.v30.i47.5070","volume":"30","author":"T Yodoshi","year":"2024","unstructured":"Yodoshi T (2024) Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 30(47):5070\u20135075","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2789_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70240","volume":"45","author":"S Romeo","year":"2025","unstructured":"Romeo S, Valenti L (2025) Fifteen years of PNPLA3: transforming hepatology through human genetics. Liver Int 45(9):e70240","journal-title":"Liver Int"},{"issue":"6","key":"2789_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2025.02.032","volume":"82","author":"PK Luukkonen","year":"2025","unstructured":"Luukkonen PK (2025) Subtypes of MASLD confer distinct clinical trajectories. J Hepatol 82(6):1138\u20131139","journal-title":"J Hepatol"},{"key":"2789_CR26","doi-asserted-by":"publisher","unstructured":"Di Sessa A, Forcina G, Frattolillo V, Cirillo G, Marzuillo P, Miraglia Del Giudice E (2026) TM6SF2 E167K in paediatric MASLD: A genetic modifier of divergent extrahepatic outcomes. Diabetes Obes Metab. 28(1):767-770. https:\/\/doi.org\/10.1111\/dom.70233","DOI":"10.1111\/dom.70233"},{"issue":"3","key":"2789_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16103","volume":"45","author":"VL Chen","year":"2025","unstructured":"Chen VL, Vespasiani-Gentilucci U (2025) Integrating PNPLA3 into clinical risk prediction. Liver Int 45(3):e16103","journal-title":"Liver Int"},{"issue":"4","key":"2789_CR28","first-page":"226","volume":"22","author":"N Stefan","year":"2025","unstructured":"Stefan N, Targher G (2025) Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine. Nat Rev Gastroenterol Hepatol 22(4):226\u2013227","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"2789_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jhep.2025.05.016","volume":"83","author":"L Valenti","year":"2025","unstructured":"Valenti L, Hagstr\u00f6m H (2025) Bringing genetic testing into the clinical management of people with MASLD: Are we there yet? J Hepatol 83(4):825\u2013827. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.016","journal-title":"J Hepatol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02789-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:11:25Z","timestamp":1776247885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02789-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["2789"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02789-w","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki and its later amendments and approved by our Ethic Committee (protocol code 834\/2016).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"An informed written consent was obtained from the parent(s) or legal guardian(s) of the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}}]}}